Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 8/20 | 0.58 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TACR2 | P21452 | 2/20 | 0.47 |
| ▸ | TACR3 | P29371 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475536 | 0.88 | DHODH (0.50) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL5476663 | 0.84 | DHODH (0.53) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL8267472 | 0.80 | LMNA (0.82) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL14492079 | 0.80 | PDE10A (0.68) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL6957665 | 0.80 | DHODH (0.65) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL1581252 | 0.80 | DHODH (0.65) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL4245187 | 0.80 | DHODH (0.65) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL6853012 | 0.79 | TACR3 (0.64) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL5436914 | 0.79 | DHODH (0.50) | DHODHPDE10ALMNATSHRPOLB | |
| SCHEMBL6222134 | 0.78 | TACR2 (0.55) | DHODHPDE10ALMNATSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142431-A1 | Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2007-06-21 | — | — | US | claimed |
| EP-1651632-A1 | QUINOLINE 4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS NEUROKININ 3 (NK-3) RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005014575-A1 | QUINOLINE 4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS NEUROKININ 3 (NK-3) RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-17 | — | — | WO | claimed |
| US-20070142431-A1 | Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2007-06-21 | — | — | US | disclosed |
| EP-1651632-A1 | QUINOLINE 4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS NEUROKININ 3 (NK-3) RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005014575-A1 | QUINOLINE 4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS NEUROKININ 3 (NK-3) RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142431-A1 | Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists | TACR3, GRIK3, TACR2 | DHODH 3942/4885PDE10A 2035/4885LMNA 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.